Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Drew Lansdown

Orthopaedic Surgery San Francisco, CA Medical Doctor

NPI 1356669899 CMS profile 1396901

500 Parnassus Ave, Mu320w, San Francisco, CA 94143

Open in the dashboard

General payments

$28,995

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,441 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Drew Lansdown of San Francisco, CA is reported in the CMS Open Payments database as having received $28,995 across 51 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $23,441 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $630 9
2024 General $16,283 16
2023 General $3,232 14
2022 General $2,879 4
2021 General $4,500 2
2020 General $127 3
2019 General $1,343 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Drew Lansdown
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Drew Lansdown were reported at $630. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Drew Lansdown Orthopaedic Surgery median Middle half National median
2019 $1,343 $644 $140–$2,844 $163
2020 $127 $312 $75–$1,860 $114
2021 $4,500 $520 $117–$2,495 $132
2022 $2,879 $598 $128–$2,731 $149
2023 $3,232 $461 $128–$2,264 $160
2024 $16,283 $497 $134–$2,475 $164
2025 $630 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Linvatec Corporation $16,542 17 payments
  2. Vericel Corporation $7,788 5 payments
  3. Evolution Surgical, Inc $2,327 4 payments
  4. Stryker Corporation $1,961 17 payments
  5. Aesculap Biologics, LLC $127 3 payments
  6. Arthrex, Inc. $98 1 payment
  7. Abanza Inc. $90 1 payment
  8. Zimmer Biomet Holdings, Inc. $38 2 payments
  9. DePuy Synthes Sales Inc. $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,263 5 payments
  2. Travel and Lodging $10,017 10 payments
  3. Food and Beverage $2,496 34 payments
  4. Education $2,220 2 payments
Products named General payments · program years 2019–2025
  1. ALLOGRAFT TISSUE $8,906 6 payments
  2. LIVATEC KNEE PRESERVATION SYSTEM $5,809 6 payments
  3. MACI Orthopedics $4,488 4 payments
  4. MACI Cellular Therapy $3,300 1 payment
  5. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $1,661 11 payments
  6. BIOBRACE 23MM $1,640 4 payments
  7. LINVATEC EXTREMITIES $298 1 payment
  8. LINVATEC SHOULDER ARTHROSCOPY $298 1 payment
  9. LINVATEC HIP PRESERVATION SYSTEM $298 1 payment
  10. LINVATEC KNEE PRESERVATION SYSTEM $298 1 payment
  11. Other $790 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

65

Median for Orthopedic Surgery: 203

Drug cost

$451

Median for Orthopedic Surgery: $1,433

Branded share of claims

23.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ibuprofen Generic 28 $302
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $88
Ondansetron Hcl Generic 22 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$86,718

Medicare's payments for the services billed

Medicare patients

204

Average age 71

Services billed

441

111 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 71%
High blood pressure 66%
Depression 24%
Diabetes 23%
Ischemic heart disease 19%
Chronic kidney disease 18%
Cancer 17%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record